Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1781. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK Full Text available with Trip Pro

, these will be referenced in the text of the abstract and their bibliographic details recorded here for information. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:5-26. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Me (...) Res Opin 2004;20:S27-S40. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9. Currie CJ, Morrisey M, Peters JR, et al. The impact of health related quality of life (EQ-5Dindex) in people with Type 1 diabetes who experience severe hypoglycaemia. Diabetologia 2005;48:A292-3. Hermansen K, Fontaine P, Kukojla KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional

2007 NHS Economic Evaluation Database.

1782. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes in the UK

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes in the UK Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes in the UK Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes in the UK McEwan P, Poole C D, Tetlow T, Holmes P, Currie C J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of insulin glargine compared with NPH insulin for patients with Type 2 diabetes. The dose regimen was 0.40 IU/kg per day for both types of insulin. Type of intervention Treatment. Economic study type Cost-utility analysis Study population

2007 NHS Economic Evaluation Database.

1783. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 1 diabetes in the UK

studies dating from 1993 to 2006. The effectiveness data related to a systematic review and meta-analyses of insulin glargine and NPH insulin and Types 1 and 2 diabetes (Medical Research Matters Limited 2006, see 'Other Publications of Related Interest' below for bibliographic details). The costs for resource outlays were derived from various current UK sources and were indexed to 2005. Modelling A discrete event simulation model with a maximum 40-year time horizon was constructed. Full details (...) for 2-year treatment effects. Authors' conclusions The authors stated that the use of insulin glargine to treat Type 1 diabetes was highly cost-effective compared with insulin NPH in the UK. The results were found to be stable whether the effectiveness was due to either a reduction in hypoglycaemia or an improvement in glycaemic control as the primary benefit. The authors considered their findings as conservative, owing to the effectiveness of glargine being higher in research designs than

2007 NHS Economic Evaluation Database.

1784. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000

Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000 Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000 Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000 Icks A, Rathmann W, Haastert B (...) , Gandjour A, Holle R, John J, Giani G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of two primary prevention strategies, lifestyle modification versus metformin, for Type 2 diabetes in a "real

2007 NHS Economic Evaluation Database.

1785. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model

Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model Campbell H M, Boardman K D, Dodd M A, Raisch D W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of treatment with or without angiotensin converting enzyme (ACE) inhibitors for patients with type 2 diabetes and normal albuminuria, microalbuminuria, or macroalbuminuria, in the USA. The authors concluded that ACE inhibitors were cost-effective and averted numerous events

2007 NHS Economic Evaluation Database.

1786. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada Grima D T, Thompson M F, Sauriol L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined glargine insulin in patients with Type 1 or 2 diabetes who had inadequate glycaemic control. The comparator was neutral protamine hagedorn (NPH) insulin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis, cost-utility analysis Study population The study population comprised two hypothetical cohorts

2007 NHS Economic Evaluation Database.

1787. The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes

The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes Lowey A, Moore S, Norris C, Wright D, Silcock J, Hammond P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a clinic-based, pharmacist-led treatment of cardiac risk for patients with Type 2 diabetes and resistant hypertension. The pharmacists monitored blood pressure (BP), prescribed antihypertensive medications, and prepared individualised information and patient education. Type of intervention Secondary

2007 NHS Economic Evaluation Database.

1788. Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States

Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States Valentine W J, Erny (...) with Type 2 diabetes in comparison with OHA alone, neutral protamine Hagedorn insulin added to OHA, and insulin glargine added to OHA. The analysis showed that Idet was a cost-effective strategy from the perspective of the US payer in patients not adequately controlled with the other treatments. Globally, the study was well conducted and presented, although some methodological aspects were reported in the published decision model study. Type of economic evaluation Cost-utility analysis Study objective

2007 NHS Economic Evaluation Database.

1789. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK Full Text available with Trip Pro

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK Valentine W J, Bottomley J M, Palmer A J, Brandle M, Foos V, Williams R, Dormandy J A, Yates J, Tan M H, Massi-Benedetti M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of pioglitazone to existing treatments ("add-on" therapy) for patients with Type 2 diabetes and a history of macrovascular disease. Pioglitazone could be given at 15, 30 or 45 mg/day. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility

2007 NHS Economic Evaluation Database.

1790. Multisystemic therapy improved adherence to blood glucose testing in adolescents with type 1 diabetes

Multisystemic therapy improved adherence to blood glucose testing in adolescents with type 1 diabetes Multisystemic therapy improved adherence to blood glucose testing in adolescents with type 1 diabetes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Multisystemic therapy improved adherence to blood glucose testing in adolescents with type 1 diabetes Article Text Treatment Multisystemic therapy improved adherence to blood glucose

2007 Evidence-Based Nursing

1791. Review: group-based education in self management strategies improves outcomes in type 2 diabetes mellitus Full Text available with Trip Pro

Review: group-based education in self management strategies improves outcomes in type 2 diabetes mellitus Review: group-based education in self management strategies improves outcomes in type 2 diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: group-based education in self management strategies improves outcomes in type 2 diabetes mellitus Article Text Therapeutics Review: group-based education in self management

2006 Evidence-Based Medicine

1792. Epidemic obesity and type 2 diabetes in Asia. (Abstract)

Epidemic obesity and type 2 diabetes in Asia. The proportions of people with type 2 diabetes and obesity have increased throughout Asia, and the rate of increase shows no sign of slowing. People in Asia tend to develop diabetes with a lesser degree of obesity at younger ages, suffer longer with complications of diabetes, and die sooner than people in other regions. Childhood obesity has increased substantially and the prevalence of type 2 diabetes has now reached epidemic levels in Asia

2006 Lancet

1793. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. (Abstract)

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (...) , reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. These new classes of antidiabetic agents, and incretin mimetics and enhancers, also expand beta-cell mass in preclinical studies. However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes.

2006 Lancet

1794. Review: group based education in self management strategies improves outcomes in type 2 diabetes mellitus Full Text available with Trip Pro

Review: group based education in self management strategies improves outcomes in type 2 diabetes mellitus Review: group based education in self management strategies improves outcomes in type 2 diabetes mellitus | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: group based education in self management strategies improves outcomes in type 2 diabetes mellitus Article Text Treatment Review: group based education in self management

2006 Evidence-Based Nursing

1795. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. Full Text available with Trip Pro

Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. The long-term outcome of persons with youth-onset type 2 diabetes mellitus has not been well described.To compare incidence of diabetic end-stage renal disease (ESRD) and mortality in Pima Indians with youth- and older-onset type 2 diabetes mellitus.Longitudinal population-based study conducted between 1965 and 2002 in Pima Indians from the state of Arizona (...) . Participants were divided into 2 groups: (1) youth-onset type 2 diabetes mellitus (onset <20 years of age) and (2) older-onset type 2 diabetes mellitus (onset > or =20 - <55 years of age). Events and person-years of follow-up were stratified in a time-dependent fashion by decades of age. End-stage renal disease was defined as dialysis attributed to diabetic nephropathy or death from diabetic nephropathy.Incidence rate of diabetic ESRD and mortality between 25 and 55 years of age, according to age at onset

2006 JAMA

1796. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. Full Text available with Trip Pro

Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. To provide perinatal mortality and congenital anomaly rates for babies born to women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland.National population based pregnancy cohort.231 maternity units in England, Wales, and Northern Ireland.2359 pregnancies to women with type 1 or type 2 diabetes who delivered between 1 (...) March 2002 and 28 February 2003.Stillbirth rates; perinatal and neonatal mortality; prevalence of congenital anomalies.Of 2359 women with diabetes, 652 had type 2 diabetes and 1707 had type 1 diabetes. Women with type 2 diabetes were more likely to come from a Black, Asian, or other ethnic minority group (type 2, 48.8%; type 1, 9.1%) and from a deprived area (type 2, 46.3% in most deprived fifth; type 1, 22.8%). Perinatal mortality in babies of women with diabetes was 31.8/1000 births. Perinatal

2006 BMJ

1797. Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Full Text available with Trip Pro

Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Article Text Therapeutics Picotamide

2006 Evidence-Based Medicine

1798. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. (Abstract)

The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. In western populations, coffee consumption is associated with a reduced risk for type 2 diabetes; however, the effect of green, black, and oolong teas is unclear.To examine the relationship between consumption of these beverages and risk for diabetes.Retrospective cohort study.25 communities across Japan.A total of 17,413 persons (6727 men and 10,686 women; 49 (...) % of the original study population) who were 40 to 65 years of age; had no history of type 2 diabetes, cardiovascular disease, or cancer at the baseline lifestyle survey; and completed the 5-year follow-up questionnaire. There was no difference in body mass index levels at baseline between respondents and nonrespondents.Questionnaire on consumption of coffee; black, green, and oolong teas; and physician-diagnosed diabetes.During the 5-year follow-up, there were 444 self-reported new cases of diabetes in 231 men

2006 Annals of Internal Medicine

1799. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Full Text available with Trip Pro

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Glycemic disorders, one of the main risk factors for cardiovascular disease, are associated with activation of oxidative stress.To assess the respective contributions of sustained chronic hyperglycemia and of acute glucose fluctuations to oxidative stress in type 2 diabetes.Case-control study of 21 patients with type 2 diabetes (studied 2003-2005) compared (...) and, more generally, during glucose swings exhibited a more specific triggering effect on oxidative stress than chronic sustained hyperglycemia. The present data suggest that interventional trials in type 2 diabetes should target not only hemoglobin A1c and mean glucose concentrations but also acute glucose swings.

2006 JAMA

1800. Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Full Text available with Trip Pro

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Article Text Therapeutics Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus Free Apoor S Gami , MD

2006 Evidence-Based Medicine